The Center of Excellence in Immunology (CEI) is one of 5 Centers of Excellence within the NCI Intramural Research Program (IRP). These Centers are multi-disciplinary venues that generate connections among diverse intellectual, financial, and physical resources within the IRP to help develop new initiatives, projects, and collaborations that reduce the burden of cancer.

Mission

The Mission of the Center of Excellence in Immunology is to foster discovery, development, and delivery of novel immunologic approaches for the prevention and treatment of cancer and cancer-associated viral diseases.

Objectives

  • Provide a format to integrate the diverse fields within immunology and facilitate translation of basic research discoveries into successful treatments
  • Serve as a distinctive think tank
  • Blend basic and clinical scientific expertise and perspectives
  • Merge disciplines and promote new perspectives
  • Provide attractive partnership options for academia and pharmaceutical companies
  • Promote interaction of immunologists in the intra- and extramural communities

 

Selected Activities

  • Save the Date!! Registration is now open for "Frontiers in Basic Immunology".  This meeting will be held September 27-28, 2018 on the Bethesda campus of the NIH. Information on the program, as well as on-line registration, is available at the meeting webpage.
  • The Immunology and Immunotherapy Seminar Series
  • Collaborations with the Center for Human Immunology
  • Collaborations with the Cancer Immunotherapy Network (CITN)
  • Partnerships with the Society for the Immunotherapy of Cancer (SITC)
  • Collaborations with Biotech and Pharma


Selected Recent Publications

Imaging of subclinical haemopoiesis after stem-cell transplantation in patients with haematological malignancies: a prospective pilot study. Williams KM, Holter-Chakrabarty J, Lindenberg L, Duong Q, Vesely SK, Nguyen CT, Havlicek JP, Kurdziel K, Gea-Banacloche J, Lin FI, Avila DN, Selby G, Kanakry CG, Li S, Scordino T, Adler S, Bollard CM, Choyke P, Gress RE.  Lancet Haematol. Jan 2018

Identification of lineage-specifying cytokines that signal all CD8+-cytotoxic-lineage-fate 'decisions' in the thymus. Etzensperger R, Kadakia T, Tai X, Alag A, Guinter TI, Egawa T, Erman B, Singer A. Nat Immunol. Nov 2017

Treatment of metastatic uveal melanoma with adoptive transfer of tumour-infiltrating lymphocytes: a single-centre, two-stage, single-arm, phase 2 study. Chandran SS, Somerville RPT, Yang JC, Sherry RM, Klebanoff CA, Goff SL, Wunderlich JR, Danforth DN, Zlott D, Paria BC, Sabesan AC, Srivastava AK, Xi L, Pham TH, Raffeld M, White DE, Toomey MA, Rosenberg SA, Kammula US.Lancet Oncol. June 2017

Landscape of immunogenic tumor antigens in successful immunotherapy of virally induced epithelial cancer. Stevanovic S, Pasetto A, Helman SR, Gartner JJ, Prickett TD, Howie B, Robins HS, Robbins PF, Klebanoff CA, Rosenberg SA, Hinrichs CS. Science. April 2017

Identification of essential genes for cancer immunotherapy.   Patel SJ, Sanjana NE, Kishton RJ, Eidizadeh A, Vodnala SK, Cam M, Gartner JJ, Jia L, Steinberg SM, Yamamoto TN, Merchant AS, Mehta GU, Chichura A, Shalem O, Tran E, Eil R, Sukumar M, Guijarro EP, Day CP, Robbins P, Feldman S, Merlino G, Zhang F, Restifo NP. Nature. Aug 2017.

Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial Christopher R Heery, Geraldine O’Sullivan-Coyne, Ravi A Madan, Lisa Cordes, Arun Rajan, Myrna Rauckhorst, Elizabeth Lamping, Israel Oyelakin, Jennifer L Marté, Lauren M Lepone, Renee N Donahue, Italia Grenga, Jean-Marie Cuillerot, Berend Neuteboom, Anja von Heydebreck, Kevin Chin, Jeffrey Schlom, James L Gulley  Lancet Oncology, May 2017

Avelumab for patients with previously treated metastatic recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial James L Gulley, Arun Rajan, David R Spigel, Nicholas Iannotti, Jason Chandler, Deborah J L Wong, Joseph Leach, W Jeff Edenfield, Ding Wang, Hans Juergen Grote, Anja von Heydebreck, Kevin Chin, Jean-Marie Cuillerot, Karen Kelly  Lancet Oncology, May 2017

Recruitment of calcineurin to the TCR positively regulates T cell activation. Dutta D, Barr VA, Akpan I, Mittelstadt PR, Singha LI, Samelson LE, Ashwell JD. Nat Immunol. Feb 2017

Cell Transfer Therapy Targeting Mutant KRAS in Cancer. Tran E, Robbins PF, Lu YC, Prickett TD, Gartner JJ, Jia L, Pasetto A, Zheng Z, Ray S, Groh EM, Kriley IR, Rosenberg SA. N Engl J Med. Dec 2016

Timing and duration of MHC I positive selection signals are adjusted in the thymus to prevent lineage errors. Kimura MY, Thomas J, Tai X, Guinter TI, Shinzawa M, Etzensperger R, Li Z, Love P, Nakayama T, Singer A. Nature Immunology. Dec 2016.

Distinct Functions of Senescence-Associated Immune Responses in Liver Tumor Surveillance and Tumor Progression. Eggert T, Wolter K, Ji J, Ma C, Yevsa T, Klotz S, Medina-Echeverz J, Longerich T, Forgues M, Reisinger F, Heikenwalder M, Wang XW, Zender L, Greten TF. Cancer Cell. Oct 2016.